Floatz logo

Ibrutinib

Recurrent Hodgkin Lymphoma

Vanderbilt-Ingram Cancer CenterSmall moleculePhase 2Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

150 Active assets in the Recurrent Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB

View all 50 →

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →